Zhejiang University proposed a new plan for the targeted treatment of acute kidney injury

。 A diagram of the chemical structure of SS31 pre-drug and its treatment of acute kidney injuryRecently, Science Advances published the latest results of the team of Du Yongzhong, a professor at Zhejiang University's School of Pharmacy. The team designed a targeted treatment drug for acute kidney injury with precise cargo, effective release, high concentration distribution and long-term stay, which provides important basic research for clinical transformation.
this was done by the research team after nearly 2 years of research.
the epithelocyt cells of the nephroblast are the most important damaged target cells for acute kidney injury. Studies have shown that when acute kidney injury occurs, the reactive oxygen in the epithelial cells of the renal tube can abnormally increase, causing mitochondrial damage, which in turn leads to apoptosis, which in this series of chain reactions leads to renal function damage.
why are there so few drugs that can inhibit this process of injury?
Because traditional antioxidant therapy does not accurately reach the epithal cells of the renal tube, even if they do, because the kidneys, as an important excretion organ of the human body, the drug is quickly excreted, unable to form a high concentration of coverage to protect the damaged mitochondrials and stop the chain damage.
, Du Yongzhong's team tried to come up with a new plan for the treatment of acute kidney injury through a long-term study of pre-drugs.
Du Yongzhong's team has innovatively designed a drug "launch vehicle" that will be able to inhibit oxidative reactions in the mitochondrial mitochondrials of the renal tube epithrea, delivered precisely and producing utility effects. SS31 is a new drug in clinical trials to treat geriatric mitochondrial disease and myocardial infarction, which can stop apoptosis by protecting mitochondrial cells in high concentrations in the epithyroid cells of the renal tube.
everything is ready, waiting for Dongfeng to deliver the drug to the acute kidney injury site.
"We designed a launch vehicle consisting of a two-stage propulsion system and payload to complete the transport function. Du Yongzhong introduced this new structure, the first stage of the rocket for the use of positive electron low molecular weight shell polysaccharides to target the drug to the kidneys, the second stage of the rocket through the interaction between serine and acute renal injury renal tube over-expression of the renal injury molecule-1 (Kim-1) targeted to the renal tube epithelial cells.
only the satellite SS31 drugs to the kidney tube, the treatment effect is still not good, only to achieve "star arrow separation", in order to form an effective drug administration system. "When the launch vehicle reaches the renal tube, it reacts with the reactive oxygen that is all over it, releasing the SS31 drug and separating the star arrow."
Du Yongzhong introduced, this mode of transport drugs, compared to SS31 original drugs, in the kidney distribution increased by 3 times, significantly improve the therapeutic effect, reduce the oxidative stress, inflammation and apoptosis of damaged kidneys, is an effective drug administration system in the treatment of acute kidney injury. "This precise step-by-step targeted administration strategy (organ-tissue-cell) can also be used in drug design for other kidney diseases." (Source: Cui Xueqin, China Science Daily)
related paper information: